Circadian Rhythm Sleep Treatment Market Size
Circadian Rhythm Sleep Treatment Market size was valued at approximately USD 104.5 million in 2025 and is projected to reach around USD 148.6 million by 2033, growing at a CAGR of 4.5% during the forecast period (2026–2033).
Circadian rhythm sleep disorders (CRSD) are sleep disorders that affect the timing of sleep. CRSDs arise from a persistent pattern of sleep/wake disturbances caused either by dysfunction in one's biological clock system or by a misalignment between one's endogenous oscillator and externally imposed cues. The primary event in circadian rhythm sleep treatment is depression of melatonin levels and irregular melatonin levels during the circadian body clock. Treatment options include bright light therapy, medications, behavioral therapy and drugs.
Circadian Rhythm Sleep Treatment Market Scope
| Metrics | Details |
| Market CAGR | 4.5% |
| Segments Covered | By Treatment Type, By Disorder Type, By Distribution Channel, By End User, and By Region |
| Report Insights Covered | Competitive Landscape Analysis, Company Profile Analysis, Market Size, Share, Growth, Demand, Recent Developments, Mergers and acquisitions, New Product Launches, Growth Strategies, Revenue Analysis, and Other key insights. |
| Fastest Growing Region | Asia Pacific |
| Largest Market Share | North America |
For More Insights Request Free Sample
Circadian Rhythm Sleep Treatment Market Dynamics
Increasing awareness about sleep disorders and technological advancements are expected to drive the circadian rhythm sleep treatment market.
The increasing prevalence of sleep disorders is expected to drive market growth.
Restless Legs Syndrome is a common disorder that affects 3-10% of the population, though the number of people affected and the severity of the condition vary by country. Furthermore, each breathing pause can last from 10 seconds to more than a minute and is accompanied by a drop in oxygen. Each hour, the events may occur 5 to 50 times or more. This strains the heart and can lead to various serious health problems.
Besides that, insomnia affects 30-45% of the adult population. Primary insomnia (insomnia caused by no underlying condition) affects 1-10% of the general population, with the elderly accounting for up to 25%. Inadequate or poor-quality sleep also makes us more prone to accidents. Insomniacs are seven times more likely than good sleepers to be involved in an accident that results in death or serious injury. According to studies, people who have insomnia exhibit more symptoms of anxiety and depression than those who do not. Therefore, there is an increase in the demand for the treatment of sleep disorders. Thus, from the above-mentioned factors, the market is expected to drive in the forecast period.
Side effects associated with the drugs to treat circadian rhythm sleep are expected to hamper the market growth.
Melatonin supplements are laboratory-created versions of the sleep hormone that a doctor may prescribe for delayed sleep-wake phase disorder, irregular sleep-wake rhythm disorder, and non-24-hour sleep-wake rhythm disorder. Aside from its benefits, the drug is associated with side effects such as dizziness and fatigue. Thus, from the above-mentioned factors, the market is expected to hamper the forecast period.
Circadian Rhythm Sleep Treatment Market Segment Analysis
Bright light therapy segment is expected to hold the largest market share in circadian rhythm sleep treatment
The segment benefits because bright light therapy is used to manage circadian rhythm disorders such as delayed sleep phase syndrome (DSPS), a condition that shifts the normal sleeping pattern outside the standard norm. People with DSPS typically do not fall asleep until several hours after midnight. They have difficulty waking up in the morning, making it difficult to maintain a normal work or school schedule. However, if they are allowed to follow their schedules, their sleep quality is otherwise normal. Bright light therapy is used to restore normal sleeping patterns gradually. The light exposure timing is critical for treatment.
Moreover, exposure to bright light in the evening may help the patient with an advanced sleep disorder. Therefore, there is an increase in the adoption of bright light therapy. Thus, from the above-mentioned factors, the market segment accounted for the largest market share in the forecast period.
Circadian Rhythm Sleep Treatment Market Geographical Share
North America region holds the largest market share in the global circadian rhythm sleep treatment
The increasing prevalence of sleeping disorders, increasing awareness about sleep disorders, product launches and collaborations by the market players, and increasing government investments in research to improve sleep are the factors to drive the market in the forecast period. Moreover, 71,000 individuals are injured annually in the United States due to sleep-related accidents. Sleep-related accidents kill 1,550 people. In addition, 46% of people with frequent sleep disturbances report missing work or events or making mistakes at work, compared to 15% of healthy sleepers. Furthermore, a study conducted in the United States estimated the annual costs of insomnia to be between $92.5 billion and $107.5 billion. Thus, from the above-mentioned factors, the North American region accounted for the largest market share in the forecast period.
Circadian Rhythm Sleep Treatment Market Companies and Competitive Landscape
Major key players in the circadian rhythm sleep treatment market are Beurer GmbH, Fitbit, Inc., Koninklijke Philips, Compass Health Brands (Carex Health), Natus Medical, Compumedics, Lucimed (Luminette), Samarit Medical AG, ResMed Inc., BMC Medical Co., Ltd and SOMNOmedics GmbH.
Teva Pharmaceutical Industries Limited:
Overview:
Teva Pharmaceutical Industries Limited is an American-Israeli pharmaceutical company that develops, manufactures, markets, and distributes generic medicines and a portfolio of specialty medicines worldwide. It operates in two separate segments, Generic Medicines and Specialty Medicines. It focuses on the central nervous system, pain, respiratory, and oncology areas. Teva API's portfolio comprises over 400 quality APIs manufactured at 16 state-of-the-art production facilities, employing over 5,000 highly-trained professionals. Teva API greatly emphasizes streamlining API development production and product lifecycle management (PLM) processes. The company scientists are known for their expertise in chemical synthesis, fermentation, high potency, plant extract, synthetic peptides, vitamin D derivatives, prostaglandins, analytical science, powder technology and solid-3 state characterization.
Product Portfolio:
Melatonin Teva XL 2mg PR Tablets: Melatonin Teva XL is indicated as monotherapy for the short-term treatment of primary insomnia characterised by poor quality of sleep in patients who are aged 55 or over.
Recent Development-
- December 2025: Vanda Pharmaceuticals continued expansion of its circadian rhythm disorder drug Hetlioz (tasimelteon) clinical positioning, with ongoing real-world evidence studies in the U.S. focusing on Non-24-Hour Sleep-Wake Disorder (Non-24) and broader circadian rhythm applications, supported by updated patient outcome data.
- November 2025: Eli Lilly and Company advanced neuroscience and sleep research collaborations targeting circadian biology and neurodegenerative-linked sleep disruption, strengthening its pipeline in sleep-wake regulation therapies through biomarker-driven approaches.
- October 2025: ResMed expanded its digital sleep platform in North America, integrating AI-driven circadian rhythm tracking and behavioral sleep therapy tools into its ecosystem, aiming to improve diagnosis and treatment adherence for sleep-wake disorders.
- December 2025: Takeda Pharmaceutical Company progressed research in orexin and circadian rhythm modulation therapies, focusing on next-generation sleep disorder treatments addressing insomnia and circadian misalignment.
- November 2025: Eisai Co., Ltd. strengthened its CNS pipeline with continued development of sleep-wake regulation therapies, emphasizing circadian rhythm stabilization in neurological disorders such as Alzheimer’s disease.
- October 2025: Fujitsu partnered with healthcare institutions in Japan to develop digital therapeutics and wearable-based circadian rhythm monitoring solutions, enabling personalized sleep treatment interventions.
The global circadian rhythm sleep treatment market report would provide an access to an approx. 45+market data table, 40+figures and 180pages.
